Our Team

We are focused on realizing the highest synergy of technology and medical science to dramatically enhance the health of people living with diabetes


about_img1Dr. Mayer B. Davidson | Chief Medical Officer

Mayer B. Davidson, MD is Professor of Medicine at both the David Geffen School of Medicine at UCLA and Charles R. Drew University. A renowned researcher and speaker on type 2 diabetes and insulin resistance, he has presented hundreds of lectures nationally and internationally and was the 1997-1998 President of the American Diabetes Association. Dr. Davidson was Founding Editor of Current Diabetes Reports and Editor-in-Chief of Diabetes Care, the leading clinical journal for the diabetes community, from 2002 through 2006. He has served on the Editorial Boards of Diabetes Care, Diabetes Spectrum, Clinical Diabetes, Diabetes Reports, Today in Medicine, Geriatrics, and The Journal of Clinical Endocrinology and Metabolism; he was a Consulting Editor of Hippocrates and an Associate Editor of Endo Trends, and he currently serves on the Editorial Board of Diabetes Research & Clinical Practice. Dr. Davidson’s contributions to medical literature include 168 scientific papers, 31 book chapters, 59 reviews, and 54 editorials and invited articles. He is the main author of the textbook Diabetes Mellitus: Diagnosis and Treatment, the 4th edition of which was published in 1998 and has been translated into Italian and Portuguese. The fifth edition, Davidson’s Diabetes Mellitus: Diagnosis and Treatment, was updated by two of his colleagues and published in 2004. Dr. Davidson was the lead author of The Complete Idiot’s Guide to Type 2 Diabetes, published in 2005 and 2009. His most recent book, Meeting the American Diabetes Association Standards of Care: An Algorithmic Approach to Clinical Care of the Diabetes Patient, was published by the American Diabetes Association in 2010. In 2016 Dr. Davidson received the American Diabetes Association’s Outstanding Physician-Clinician Award. Dr. Davidson’s Curriculum Vitae

about_img2Josh Davidson | Chief Executive Officer

Josh spent the first 13 years of his career in the computer and video game industry, working as a producer, marketer, business development manager, and operations manager for Microsoft, DreamWorks Interactive, Kalisto Entertainment, and Arena.net. Josh has managed multimillion-dollar development teams and helped negotiate and execute investment and sale transactions for technology and technology related companies. After working on many top 10 titles and doing the business planning and capital raising for multiple startup companies, Josh left the games industry to pursue his interests in trading, venture capital, and business consulting.

about_img3Michael Margolese | Chief Technology Officer

Michael worked 15 years as an electrical engineer in the defense and commercial electronics industries and specializes in mixed signal circuit design, digital communications, and digital signal processing. While working at Xilinx, Inc. he received 4 patents and led the development of a wideband software-defined radio platform. Michael was a Project Lead and Senior Hardware Engineer at L-3 Communications Power Paragon division in Anaheim, California. After finishing work at L-3 Communications Michael moved on to DCX-CHOL as a senior hardware engineer where he helped develop the next generation of hand-held military aircraft payload test sets. Also Michael is a project lead and senior digital systems analyst at AEI doing worst case analysis for the commercial & defense satellite industry. He has also worked for 4 years at algorithm and software development for FX Internals focusing on the next generation of software for Forex and Futures in market analysis and trading.

about_img4Craig Lewis | Chief Operating Officer

Craig is a 20-year veteran of the financial services industry including his tenure as Senior Executive Vice President of MBNA America Bank where he helped launch the affinity credit card industry. He led the marketing and partnership efforts for hundreds of the banks’ key relationships including Stanford University, Los Angeles Lakers, and NASCAR and oversaw a $3 billion portfolio of consumer loans. His other experience includes entrepreneurial ventures in real estate investment, construction, health care, and hedge funds. Craig graduated from Georgetown University with a degree in Economics and has an MBA from Wharton.


Dr John Buse - Insulin Algorithms Medical Advisory BoardDr. John B. Buse 

John B. Buse, M.D., Ph.D. is the Verne S. Caviness Distinguished Professor of Medicine, Director of the Diabetes Care Center, Chief of the Division of Endocrinology and Executive Associate Dean of Clinical research at UNC, where he is the principal investigator on numerous studies in the prevention and treatment of type 1 and type 2 diabetes mellitus. Dr. Buse served as President of Medicine and Science for the American Diabetes Association in 2008, and in 2011 he was appointed as Chair of the National Diabetes Education Program. Dr. Buse has authored more than 200 publications and received numerous awards and honors, including the 2010 Castle Connolly National Physician of the Year award.

blog_img6Dr. Vivian A. Fonseca 

Vivian A. Fonseca, M.D., F.R.C.P. is Professor of Medicine and Alumni Chair in Diabetes, in the Section of Endocrinology, at Tulane University’s Health Sciences Center. He is the principal investigator of the DRMS (diabetes remote management system) study, which is designed to evaluate the effectiveness and possibilities of using a remote technology system to enhance and manage daily care for patients with type 2 diabetes. Dr. Fonseca has conducted trials for most diabetes drugs on the market. A former President of Medicine and Science for the American Diabetes Association, he is editor in chief of the Journal of Diabetes Complications and has served as editor in chief  of Diabetes Care and the Journal of the Metabolic Syndrome and Related Disorders. He was also on the editorial board of the Journal of Clinical Endocrinology and Metabolism.

Dr. Anne Peters

Anne Peters, M.D. is a Professor of Medicine at the Keck School of Medicine of the University of Southern California, Director of the USC Clinical Diabetes Programs. She previously directed the clinical diabetes programs at Cedars-Sinai and UCLA. Dr. Peters’ research has focused on new approaches to diagnose and treat diabetes and on the development of care systems that improve outcomes in diabetic populations. She has served on the editorial boards of several journals and published over 200 peer-reviewed articles, reviews, chapters and abstracts as well as three books. She has received many awards and been recognized for her contributions by the American Diabetes Association, the American Association for the Advancement of Science, Best Doctors in America, the National Institutes of Health, the American Medical Women’s Association and other leading institutions.

Dr. Richard A. Kahn

Richard A. Kahn, Ph.D. is an independent consultant/researcher and clinical professor of medicine at the University of North Carolina School of Medicine. A senior staff member of the American Diabetes Association from 1985 until his retirement from the Association in 2009, Dr. Kahn was the Chief Scientific and Medical Officer and was responsible for all the scientific and medical affairs of the Association. Prior to joining the American Diabetes Association and while working as Chief of Scientific Affairs for the American Red Cross in Saint Louis, Missouri, Dr. Kahn established the first tissue bank in the Red Cross System and directed a large research laboratory concerned with the pathophysiology of blood cells and the prevention of transfusion-transmitted diseases.



bio-ghutchinsonGary Hutchinson | Senior Corporate Advisor

Gary Hutchinson is an entrepreneurial executive with more than 25 years in healthcare technology. He is the CEO of ThelioPulse, a spinoff company from the Alfred E. Mann Institute at the University of Southern California (AMI USC), where he is Entrepreneur in Residence. He is also an Adjunct Lecturer at the UCLA Anderson School of Management/Global Access Program. Mr. Hutchinson served as President and CEO of Precision Dynamics Corporation from 2002 to 2010, and under his leadership the company grew from $43 million to $112 million in sales and $2 million to $16 million in EBITDA. Before Precision Dynamics Corporation, he was a founder of Zymed Medical Systems (now Phillips Medical Systems), which became the leader in ambulatory monitoring and arrhythmia algorithms and grew to $25 million in sales and $5 million in EBITDA. After its acquisition in 2000, he served as VP of Phillips’ $200 million Cardiology Products unit. Mr. Hutchinson has experience on the advisory boards of a number of companies, including ORFID, an early-stage company in organic semiconductors and polymer-based radio frequency identification devices at UCLA. He has served on the board of directors for AdvaMed, a healthcare industry advocacy organization; Quinton Instruments, a leader in stress testing; and Cardiac Rehab and Cardiac Imaging Systems. As an investor with HP, WR Hambrecht & Zymed, he led a buyout of Quinton from American Home Products.

Scott Fuller Seton Ascension Insulin AlgorithmsScott Fuller | Corporate Advisor

Scott Fuller, FACHE is Senior Vice President of Joint Ventures and Alliances at Seton Healthcare Family. He joined Seton in 2006 as Vice President and Chief Operating Officer for Seton Highland Lakes Hospital and its health centers. During his tenure with Seton, he went on to run both Seton Highland Lakes and Seton Northwest Hospitals. After serving as Assistant Executive Director of Financial Planning for Scott & White Health, he also served as Director of Strategic and Financial Planning for Phoenix Children’s Hospital. His financial background spans investment banking with Shattuck Hammond Partners, Inc., including mergers, acquisitions and divestitures, financial advisory and tax-exempt debt underwriting, commercial real estate and strategic capital planning. Fuller is a graduate of the Ascension Health Executive Formation Program, class of 2010. He earned his Bachelor of Science from Brigham Young University in 1992 and his Master of Health Services Administration in 1994 from Arizona State University, W.P. Carey School of Business.

headshot_ericwEric J. Weissman | Corporate Advisor

Eric Weissman is President of London & Pacific Capital Advisors, LLC (LPCA), a licensed broker dealer providing corporate finance services to healthcare companies. Prior to joining LPCA, he was an independent corporate finance advisor to mid-market healthcare companies. Eric has worked as an investment banker at Huntington Securities LLC, a Los Angeles-based merchant and investment banking firm, and at The Phoenix Group, where he specialized in sell-side M&A engagements, management buyouts, and leveraged ESOP transactions. Eric started his career in the mergers and acquisitions group at PricewaterhouseCoopers in Philadelphia. His clients have included multibillion-dollar pharmaceutical companies, public utilities and technology companies, as well as mid-market medical device manufacturers, consumer product manufacturers, and entertainment companies, on transactions ranging from $1 million to $8 billion. Eric graduated from Princeton University with a degree in Economics and a personal concentration in Ethics. He obtained a J.D. from the William and Mary School of Law, and maintains a current license as a member of the Virginia State Bar. He is also a licensed Securities Principal.


Insulin Algorithms - Team - Rick KahnRick Kahn | Director of Sales and Business Development

Focused on business opportunities with key healthcare distributors, providers and pharmacies, Rick has a passion for innovations that leverage technology to improve clinical outcomes. He came to Insulin Algorithms in 2015 with more than 30 years of experience in senior sales, sales management and business development at IT and healthcare companies. Rick has extensive experience working for and with SME and Fortune 500 companies, including Hewlett-Packard/ DEC, Oracle and SAP BusinessObjects.

Prior to joining Insulin Algorithms, Rick spent three years with the Hospital Association of Southern California, marketing its proprietary comparative revenue analytics and benchmarking solution to more than 100 hospitals and hospital associations across the United States.

Insulin Algorithms - Team - Uri BasanovUri Basanov | Vice President of Sales and Business Development in Europe, the Middle East and Africa

Uri Basanov comes to Insulin Algorithms with more than 25 years of experience building strategic engagements with tier-1 prospects and developing global sales channels in IoT, telemedicine, SaaS-based solutions and enterprise communications.

Prior to joining Insulin Algorithms, Uri served as Vice President of Sales for Tadiran Telecom. He built and operated the international sales division for the company’s telecommunication and SaaS products, and developed a network of value-added resellers to large enterprise and governmental agencies. Before that, Uri was the International Business Development Director at DSP Group, where he led sales of IoT, m-Health and telemedicine solutions for service providers across the globe. He has also held key sales management and business development positions at XILINX and CEVA-DSP, a representative position at Lucent Microelectronics, and engineering positions for Philips Semiconductors and Integral Technologies.


Hogan Lovells, advisory firm to Insulin AlgorithmsWith 2,500 lawyers on six continents, Hogan Lovells offers extensive experience and insights gained from working in some of the world’s most complex legal environments and markets for corporations, financial institutions and governments.

Insulin Algorithms’ primary contacts at Hogan Lovells are Barry L. Dastin and Yarmela Pavlovic.

Insulin Algorithms - Advisory Firms - Barry L Dastin, Hogan LovellsBarry L. Dastin, Hogan Lovell’s Office Managing Partner in Los Angeles, has led a number of high-profile deals, including representing the board of Harrah’s Entertainment in the $28 billion sale of the company and the senior management team of Albertsons in the $9 billion acquisition of Safeway. He has represented companies in industries ranging from computers and technology, manufacturing and retailing, entertainment, media and telecommunications, and the energy sector, to healthcare, real estate investment trusts, defense and aerospace, and investment and commercial banking. Barry has also served as outside securities and general counsel to various public and private companies.

Yarmela Pavlovic - Insulin Algorithms - Hogan LovellsYarmela Pavlovic, a Hogan Lovells partner in San Francisco, fully understands product development and product submissions (510(k)s, Investigational Device Exemptions, and Premarket Approvals), as well as other device-related regulatory issues. She has particular experience in the area of FDA regulation of digital and mobile health technology, as well as medical software and applications. Before joining Hogan Lovells, Yarmela defended medical device manufacturers and pharmaceutical companies in products liability litigation at a Philadelphia law firm. While in law school, she served as the publication manager for the Michigan Journal of Gender & Law. Yarmela also spent a summer clerking for the Portland Federal Public Defender.


Cooley LLP, advisory firm to Insulin AlgorithmsCooley’s attorneys solve legal issues for entrepreneurs, investors and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters and bet-the-company litigation, often where innovation meets the law. Cooley has more than 700 lawyers across eleven offices in the United States and China.

Christopher Shoff, Cooley LLPInsulin Algorithms’ primary advisor at Cooley is Christopher Shoff, a member of the firm’s Emerging Companies practice group and a founding partner of its Los Angeles office. Chris focuses his practice on the representation of high growth companies in a broad range of industries, including software, digital media and entertainment, mobile, consumer Internet, clean tech, medical device, pharmaceutical and healthcare services. Chris also regularly represents venture capital and private equity firms and strategic investors in connection with investments and M&A transactions. Chris was selected as a Rising Star in 2013 and 2014 by Southern California Super Lawyers magazine. He earned his JD at Harvard Law School and graduated summa cum laude from Webber State University with a BS in Economics.


SoCal IP, advisory firm to Insulin AlgorithmsSoCal IP Law Group handles intellectual property matters for high technology and high growth companies. This work involves patents, trademarks, copyrights, trade secrets, licenses and IP-related business transactions.

Steven C. Sereboff, SoCal IP, advisor to Insulin AlgorithmsInsulin Algorithms’ primary advisor at SoCal IP is Steven C. Sereboff. Sereboff has specialized in intellectual property law since 1991. His practice includes licensing and contracts, patents, trademarks, copyrights and trade secrets. He holds a B.S. degree in Electrical Engineering from the University of Maryland, and had seven years of experience in the computer software business before earning his law degree from Boston University. While at Boston University, Mr. Sereboff founded Boston University’s Technology, Science and Law Association, and was employed by MIT to negotiate and manage software licenses. His technical expertise includes many aspects of computers (both software and hardware) and myriad electronic and electrical devices, their operation and manufacture. Sereboff earned his JD from Boston University and graduated from the University of Maryland with a Bachelor of Science in Electrical Engineering.

Share This